An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti
- Alabama
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti
- Arizona
-
-
California
-
Los Angeles, California, Stati Uniti
- California
-
-
Colorado
-
Denver, Colorado, Stati Uniti
- Colorado
-
-
Florida
-
Bradenton, Florida, Stati Uniti
- Florida
-
Miami, Florida, Stati Uniti
- Florida
-
-
Illinois
-
Evanston, Illinois, Stati Uniti
- Illinios
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti
- Indiana
-
-
Massachusetts
-
Burlington, Massachusetts, Stati Uniti
- Massachusetts
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti
- Michigan
-
Detroit, Michigan, Stati Uniti
- Michigan
-
-
Missouri
-
St Louis, Missouri, Stati Uniti
- Missouri
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti
- Nebraska
-
-
New York
-
New York, New York, Stati Uniti
- New York
-
Rochester, New York, Stati Uniti
- New York
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti
- North Carolina
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti
- Ohio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti
- Pennsylvania
-
-
Texas
-
Dallas, Texas, Stati Uniti
- Texas
-
Houston, Texas, Stati Uniti
- Texas
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male and female participants between the ages of 18 and 65 years
- History of orthotopic liver transplantation less than 10 years before the Screening visit but no sooner than 6 months before Day 1
- Taking a stable immunosuppressant regimen based on either tacrolimus or cyclosporine without substantial dose changes over the past 3 months
- Naive to pegylated interferon/ribavirin treatment or experienced with pegylated interferon/ribavirin prior to transplantation with relapse, partial, or null response
Exclusion Criteria:
- Documented cirrhosis after liver transplantation
- Ascites or hepatic encephalopathy within 6 months before Screening
- Retransplantation for recurrent hepatitis C
- Treatment for hepatitis C post liver transplantation
- History within the past 3 months of: rejection within 3 months or greater than (>) 1 rejection within 12 months
- Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (<5 milligram per day) is permitted
- History within 3 months of any bacterial infection requiring >1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with end-organ involvement, fungal disease (except cutaneous and mild oral thrush)
- History of post transplant lymphoproliferative disease
- Acceptable laboratory values at Screening as specified in the protocol
- Positive for human immunodeficiency virus 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or Hepatitis B deoxyribonucleic acid (DNA) or Hepatitis B surface antigen
- History of hepatocellular carcinoma with high risk of recurrence
- Any other cause of liver disease deemed clinically significant by the investigator in addition to hepatitis C
- Autoimmune-mediated disease
- History of acute pancreatitis within 5 years before the Screening visit
- Prior treatment with an hepatitis C virus (HCV) protease inhibitor
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: T/PR + Immunosuppressant Regimen (Tacrolimus)
Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tavoletta
Altri nomi:
Tavoletta
Altri nomi:
Iniezione sottocutanea
Altri nomi:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
|
Sperimentale: T/PR + Immunosuppressant Regimen (Cyclosporine)
Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tavoletta
Altri nomi:
Tavoletta
Altri nomi:
Iniezione sottocutanea
Altri nomi:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
Lasso di tempo: 12 weeks after last planned dose of study drug (up to Week 60)
|
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (<lower limit of quantification) at 12 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 international units per milliliter (IU/mL).
|
12 weeks after last planned dose of study drug (up to Week 60)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
Lasso di tempo: 24 weeks after last planned dose of study drug (up to Week 72)
|
SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL.
|
24 weeks after last planned dose of study drug (up to Week 72)
|
|
Percentage of Participants With Rapid Viral Response (RVR)
Lasso di tempo: Week 4
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.
|
Week 4
|
|
Percentage of Participants With Extended Rapid Viral Response (eRVR)
Lasso di tempo: Week 4 and Week 12
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.
|
Week 4 and Week 12
|
|
Percentage of Participants With On-Treatment Virologic Failure
Lasso di tempo: Baseline up to Week 48
|
On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks).
Data for this outcome was not planned to be reported by prior response.
|
Baseline up to Week 48
|
|
Percentage of Participants With Viral Relapse
Lasso di tempo: 48 weeks
|
48 weeks
|
|
|
Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)
Lasso di tempo: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications
Lasso di tempo: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Biopsy Confirmed and Treated Rejection
Lasso di tempo: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage
Lasso di tempo: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Lasso di tempo: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: Baseline up to Week 52
|
Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not.
An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug.
SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
"Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.
|
Baseline up to Week 52
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Lasso di tempo |
|---|---|
|
Percentage of Participants With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
Lasso di tempo: 4 weeks after last planned dose of study drug (up to Week 52)
|
4 weeks after last planned dose of study drug (up to Week 52)
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie del fegato
- Flaviviridae Infezioni
- Epatite, virale, umana
- Epatite
- Epatite C
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Antimetaboliti
- Agenti antineoplastici
- Fattori immunologici
- Interferoni
- Interferone-alfa
- Ribavirina
- Peginterferone alfa-2a
- Interferone alfa-2
- Agenti immunosoppressivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- VX11-950-117
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .